Australian study reveals how breast cancer drugs are actually used
NCT ID NCT06624020
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This completed study looked at medical records of over 1,100 people in Australia who took CDK4/6 inhibitors (like palbociclib) for advanced or metastatic breast cancer. Researchers wanted to understand patient characteristics, dosing, and how long people stayed on treatment in real-world settings. No new treatments were given; this was a data review only.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer Australia
Sydney, New South Wales, 2000, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a radioactive tracer pinpoint Cancer's first stop?
- Can a personalized exercise program boost recovery in cancer survivors?
- Smartwatch could spot nerve damage before it starts
- Could ionized gas help fight breast cancer after surgery?
- Radiation may let breast cancer patients keep their nipple
- Can a smart digital program restore sleep for cancer survivors?